12:00 AM
Feb 11, 2013
 |  BC Week In Review  |  Clinical News  |  Clinical Status

Azilect rasagiline: Phase IV started

Teva began the double-blind, placebo-controlled, U.S. Phase IV MODERATO trial to evaluate once-daily 1 mg oral Azilect for 24 weeks in about 170 patients. The product is approved to treat signs and symptoms of PD as first-line monotherapy and as adjunct therapy...

Read the full 189 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >